Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | POLD1 | P28340 | 1/20 | 0.45 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 3/20 | 0.39 |
| ▸ | DTYMK | P23919 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786921 | 1.00 | F2 (0.48) | F2POLBPOLA1POLD1PLCD1 | |
| SCHEMBL24913467 | 0.87 | PLCD1 (0.45) | F2PLCD1 | |
| SCHEMBL21786783 | 0.87 | F2 (0.54) | F2POLB | |
| SCHEMBL19662403 | 0.87 | F2 (0.54) | F2POLB | |
| SCHEMBL21786782 | 0.87 | F2 (0.54) | F2POLB | |
| SCHEMBL21786887 | 0.87 | PLCD1 (0.45) | F2PLCD1 | |
| SCHEMBL21786892 | 0.87 | PLCD1 (0.45) | F2PLCD1 | |
| SCHEMBL19662605 | 0.87 | PLCD1 (0.45) | F2PLCD1 | |
| SCHEMBL21786781 | 0.87 | POLB (0.52) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL21786890 | 0.86 | POLG (0.45) | F2POLBPLCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | F2 4167/4885POLB 12/4885POLA1 126/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | F2 4229/4885POLB 11/4885POLA1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.